Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Escudier, Bernard; Eisen, Tim; M. Stadler, Walter; Szczylik, Cezary; Oudard, Stéphane; Staehler, Michael; Negrier, Sylvie; Chevreau, Christine; A. Desai, Apurva; Rolland, Frédéric; Demkow, Tomasz; E. Hutson, Thomas; Gore, Martin; Anderson, Sibyl; Hofilena, Gloria; Shan, Minghua; Pena, Carol; Lathia, Chetan; M. Bukowski, Ronald

doi:10.1200/jco.2008.19.5511

Public

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Shared by NobleBlocks on Jul 10, 2009 • 12:00 AM UTC

Authors:

Bernard Escudier

Tim Eisen

Walter M. Stadler

Abstract

Purpose Mature survival data and evaluation of vascular endothelial growth factor (VEGF) as a prognostic biomarker from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study in patients with renal cell carcinoma (RCC) are reported. Patients and Methods Nine hundred three pr...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!